RxDoctor Payments Data

Sunit Singhal, MD

Internal Medicine · Norcross, GANPI 1043282163

Payments from drug & device makers

$582in general payments, 2019–2025

Across 21 payments — averaging $27.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$144
  • Lumenis BE Inc$140
  • AbbVie$91
  • Amarin Pharma, Inc.$58
  • Novo Nordisk$54
  • Merz North America, Inc.$41
  • plus $54 from 3 others

What the payments were for

  • Food & beverage$582100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK7$144
Lumenis BE Inc1$140
AbbVie(2 entities)5$91
Amarin Pharma, Inc.1$58
Novo Nordisk3$54
Merz North America, Inc.1$41
Pfizer1$25
Abbott1$17
Merck1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$582 in reported general payments places this provider in the 55th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$246,939
Medicare patients
374
Services billed
5,916

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate38$51,028
MounjaroTirzepatide36$50,874
OzempicSemaglutide38$48,500
EliquisApixaban23$20,962
XareltoRivaroxaban21$16,001
MyrbetriqMirabegron11$14,783
SymbicortBudesonide/Formoterol Fumarate15$3,853
Gabapentin120$2,547
Levothyroxine Sodium309$2,454
Asa-Butalb-Caffeine-CodeineCodeine/Butalbital/Asa/Caffein13$2,337
Losartan Potassium271$1,859
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,741
Atorvastatin Calcium202$1,574
SynthroidLevothyroxine Sodium27$1,571
Albuterol Sulfate HfaAlbuterol Sulfate63$1,549

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$12$51,02838 claims
Novo NordiskOzempic$54$48,50038 claims
PfizerEliquis$25$20,96223 claims
AbbVieSynthroid$91$1,57127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Norcross

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →